Samantha Truex is currently an Advisor to Atlas Venture. Sam has over 20 years of experience in the biopharma industry. Her most recent role was as Chief Business Officer of Padlock Therapeutics, where she was instrumental in the swift progression of the company from founding to a competitive process resulting in the sale to Bristol-Myers Squibb earlier this year. Prior to Padlock, Sam spent 8 years each at Biogen and Genzyme. At Biogen, Sam served as Vice President of Corporate Development, leading negotiations of multiple licensing, collaboration and acquisition transactions. During her years at Biogen, Sam also served as program executive during the launch phase for FAMPYRA®, a small molecule for treatment of walking impairment in patients with multiple sclerosis, and for two long-lasting hemophilia factors during their clinical development phase; these are now marketed as ELOCTATE™ and ALPROLIX™. At Genzyme, Sam handled licensing and M&A transactions across multiple business units, including for Genzyme Molecular Oncology and Genzyme Genetics. Earlier in her career, Sam worked in business development for Chiron Diagnostics and at consulting firm Health Advances. Sam earned a BA in biology from Dartmouth College, a BE in biomedical engineering from the Thayer School at Dartmouth College and an MBA from the Tuck School at Dartmouth.